Merck KGaA Full Year 2023 Earnings: In Line With Expectations

Merck KGaA (ETR:MRK) Full Year 2023 Results

Key Financial Results

• Revenue: €21.0b (down 5.6% from FY 2022).
• Net income: €2.82b (down 15% from FY 2022).
• Profit margin: 14% (down from 15% in FY 2022). The decrease in margin was driven by lower revenue.
• EPS: €6.50 (down from €7.65 in FY 2022).

MRK Products In Clinical Trials

• Phase I: 5.
• Phase II: 5.
• Phase III: 4.

MRK Post-Clinical Trial Products

• Pre-registration: 1.
• Approved (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Merck KGaA Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.

Performance of the German Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Merck KGaA's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.